Manas R Biswal1, Howard M Prentice2, C Kathleen Dorey3, Janet C Blanks4. 1. Integrative Biology PhD Program, Florida Atlantic University, Boca Raton, Florida, United States. 2. Center for Complex Systems and Brain Sciences, Charles E. Schmidt College of Science, Florida Atlantic University, Boca Raton, Florida, United States Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, Florida, United States. 3. Virginia Tech Carilion School of Medicine, Roanoke, Virginia, United States. 4. Center for Complex Systems and Brain Sciences, Charles E. Schmidt College of Science, Florida Atlantic University, Boca Raton, Florida, United States.
Abstract
PURPOSE: Müller cells, the major glial cell in the retina, play a significant role in retinal neovascularization in response to tissue hypoxia. We previously designed and tested a vector using a hypoxia-responsive domain and a glial fibrillary acidic protein (GFAP) promoter to drive green fluorescent protein (GFP) expression in Müller cells in the murine model of oxygen-induced retinopathy (OIR). This study compares the efficacy of regulated and unregulated Müller cell delivery of endostatin in preventing neovascularization in the OIR model. METHODS: Endostatin cDNA was cloned into plasmids with hypoxia-regulated GFAP or unregulated GFAP promoters, and packaged into self-complementary adeno-associated virus serotype 2 vectors (scAAV2). Before placement in hyperoxia on postnatal day (P)7, mice were given intravitreal injections of regulated or unregulated scAAV2, capsid, or PBS. Five days after return to room air, on P17, neovascular and avascular areas, as well as expression of the transgene and vascular endothelial growth factor (VEGF), were compared in OIR animals treated with a vector, capsid, or PBS. RESULTS: The hypoxia-regulated, glial-specific, vector-expressing endostatin reduced neovascularization by 93% and reduced the central vaso-obliteration area by 90%, matching the results with the unregulated GFAP-Endo vector. Retinas treated with the regulated endostatin vector expressed substantial amounts of endostatin protein, and significantly reduced VEGF protein. Endostatin production from the regulated vector was undetectable in retinas with undamaged vasculature. CONCLUSIONS: These findings suggest that the hypoxia-regulated, glial cell-specific vector expressing endostatin may be useful for treatment of neovascularization in proliferative diabetic retinopathy. Copyright 2014 The Association for Research in Vision and Ophthalmology, Inc.
PURPOSE: Müller cells, the major glial cell in the retina, play a significant role in retinal neovascularization in response to tissue hypoxia. We previously designed and tested a vector using a hypoxia-responsive domain and a glial fibrillary acidic protein (GFAP) promoter to drive green fluorescent protein (GFP) expression in Müller cells in the murine model of oxygen-induced retinopathy (OIR). This study compares the efficacy of regulated and unregulated Müller cell delivery of endostatin in preventing neovascularization in the OIR model. METHODS:Endostatin cDNA was cloned into plasmids with hypoxia-regulated GFAP or unregulated GFAP promoters, and packaged into self-complementary adeno-associated virus serotype 2 vectors (scAAV2). Before placement in hyperoxia on postnatal day (P)7, mice were given intravitreal injections of regulated or unregulated scAAV2, capsid, or PBS. Five days after return to room air, on P17, neovascular and avascular areas, as well as expression of the transgene and vascular endothelial growth factor (VEGF), were compared in OIR animals treated with a vector, capsid, or PBS. RESULTS: The hypoxia-regulated, glial-specific, vector-expressing endostatin reduced neovascularization by 93% and reduced the central vaso-obliteration area by 90%, matching the results with the unregulated GFAP-Endo vector. Retinas treated with the regulated endostatin vector expressed substantial amounts of endostatin protein, and significantly reduced VEGF protein. Endostatin production from the regulated vector was undetectable in retinas with undamaged vasculature. CONCLUSIONS: These findings suggest that the hypoxia-regulated, glial cell-specific vector expressing endostatin may be useful for treatment of neovascularization in proliferative diabetic retinopathy. Copyright 2014 The Association for Research in Vision and Ophthalmology, Inc.
Authors: Eyal Banin; Michael I Dorrell; Edith Aguilar; Matthew R Ritter; Christopher M Aderman; Alexandra C H Smith; Jeffrey Friedlander; Martin Friedlander Journal: Invest Ophthalmol Vis Sci Date: 2006-05 Impact factor: 4.799
Authors: Alberto Auricchio; Kathryn C Behling; Albert M Maguire; Erin M O'Connor; Jean Bennett; James M Wilson; Michael J Tolentino Journal: Mol Ther Date: 2002-10 Impact factor: 11.454
Authors: Farshad Abedi; Sanjeewa Wickremasinghe; Andrea J Richardson; Amirul F M Islam; Robyn H Guymer; Paul N Baird Journal: Ophthalmology Date: 2013-04-09 Impact factor: 12.079
Authors: Anne Louise Askou; Jean-Antoine C Pournaras; Maria Pihlmann; Jesper D Svalgaard; Yvan Arsenijevic; Corinne Kostic; Toke Bek; Frederik Dagnaes-Hansen; Jacob Giehm Mikkelsen; Thomas Gryesten Jensen; Thomas J Corydon Journal: J Gene Med Date: 2012-11 Impact factor: 4.565
Authors: Magali Saint-Geniez; Arindel S R Maharaj; Tony E Walshe; Budd A Tucker; Eiichi Sekiyama; Tomoki Kurihara; Diane C Darland; Michael J Young; Patricia A D'Amore Journal: PLoS One Date: 2008-11-03 Impact factor: 3.240
Authors: Manas R Biswal; Howard M Prentice; George W Smith; Ping Zhu; Yao Tong; C Kathleen Dorey; Alfred S Lewin; Janet C Blanks Journal: J Mol Med (Berl) Date: 2018-08-13 Impact factor: 4.599
Authors: Michael Whitehead; Sanjeewa Wickremasinghe; Andrew Osborne; Peter Van Wijngaarden; Keith R Martin Journal: Expert Opin Biol Ther Date: 2018-11-14 Impact factor: 4.388
Authors: Cristhian J Ildefonso; Henrique Jaime; Emily E Brown; Ryo L Iwata; Chulbul M Ahmed; Michael T Massengill; Manas R Biswal; Shannon E Boye; William W Hauswirth; John D Ash; Qiuhong Li; Alfred S Lewin Journal: Invest Ophthalmol Vis Sci Date: 2016-02 Impact factor: 4.799